Australia's CSL tanks on trimming annual forecasts, flagging $5 billion impairments

Csl

11/05/2026 01:23

** Shares of CSL CSL.AX fall as much as 15.3% to A$101.51, their lowest since mid-January 2017

** Stock logs largest intraday pct loss since late October 2025

** Biotech major trims fiscal 2026 earnings and revenue outlook

** Attributes downgrade to delays in payoff from growth initiatives and revenue headwinds from U.S. immunoglobulin inventory normalisation

** Flags $5 billion of non-cash impairments over FY26-27

** Citi says revenue and NPATA growth guides have now turned negative

** Brokerage says at this point, investor trust is likely to decline further

** Stock down over 40% YTD, including day's moves

 (Reporting by Nikita Maria Jino in Bengaluru)

 ((Nikita.Jino@thomsonreuters.com;))